Clinical predictive value of naive and memory T cells in advanced NSCLC.

ABSTRACT: Currently, there is no sensitive prognostic biomarker to screen out benefit patients from the non-benefit population in advanced non-small cell lung cancer patients (aNSCLCs). The 435 aNSCLCs and 278 normal controls (NCs) were recruited. The percentages and absolute counts (AC) of circulating naïve and memory T lymphocytes of CD4⁺ and CD8⁺ T cells (Tn/Tm) were measured by flow cytometry. The percentage of CD4⁺ naïve T (Tn), CD8⁺ Tn, CD8⁺ T memory stem cell (Tscm), and CD8⁺ terminal effector T cell decreased obviously. Still, all AC of Tn/Tm of aNSCLCs was significantly lower compared to NCs. Higher AC and percentage of CD4⁺ Tn, CD8⁺ Tn, and CD4⁺ Tscm showed markedly longer median PFS in aNSCL

SUBMITTER: Zhang G 

PROVIDER: S-EPMC9478592 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature